摘要
目的:回顾性分析吉非替尼(Gefitnib,ZD1839,Iressa,易瑞沙)联合XELOX方案治疗转移性结直肠癌的临床疗效和毒副反应。方法:30例晚期转移性结直肠癌患者均经病理组织学以及影像学证实。吉非替尼给药剂量和方法为250mg,每日1次。联合化疗方案为XELOX方案(奥沙利铂+卡培他滨)。按照RECIST标准评价近期疗效,毒性反应按照WHO抗癌药物急性和亚急性毒性表现和分级标准评价。结果:30例患者部分缓解(PR)为36.7%(11/30),稳定(SD)为40.0%(12/30),疾病进展(PD)为23.3%(7/30)。临床有效率(PR+SD)为76.7%。主要毒性反应为白细胞下降(43.3%),恶心呕吐(40.0%)以及皮疹(53.3%)。结论:初步观察表明,吉非替尼联合化疗治疗转移性结直肠癌具有较好的疗效,毒副反应低,耐受性好,值得进一步研究。
Objective：To observe the efficacy and safety of Gefitnib combined with the chemotherapy for metastatic colorectal cancer.Methods： Gefitnib combined with XELOX chemotherapy agents was administrated to 30 cases with metastatic colorectal cancer confirmed by histopathology cytopathology or imaging.The dosage of Gefitnib was 250mg.The chemotherapy agents was Oxaliplatin and Capecitabine.The efficacy was evaluated strictly according to RECIST criteria.Toxicity was evaluated according to WHO anticancer drug acute and subacute toxicity levels.Results： PR rate was 36.7%,SD rate was 40.0%,PD rate was 23.3%,disease control rate（DCR） was 76.7%.The major toxic reactions were myelotoxicity,gastrointestinal tract toxicity and rash.Conclusion： Gefitnib combined with chemotherapy in the treatment of metastatic colorectal cancer showed good efficacy,and with low toxic reaction.
出处
《现代肿瘤医学》
CAS
2012年第11期2354-2357,共4页
Journal of Modern Oncology
关键词
吉非替尼
大肠癌
靶向治疗
化疗
Gefitnib
colorectal cancer
target therapy
chemotherapy
